1157 / 1816
Ziekte vrije overleving
Non-inferiority trial
Primaire eindpunt scenario’s
• PHARE failed to show that 6 m of trastuzumab is non inferior to 12 months
•Longer follow up is needed
•Other trial results are expected (shorther & SOLD trial)
1 year trastuzumab adjuvant will be daily practice